

# Larry V Rubinstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7047041/publications.pdf>

Version: 2024-02-01

59  
papers

9,667  
citations

126858

33  
h-index

143943

57  
g-index

59  
all docs

59  
docs citations

59  
times ranked

9370  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas. <i>Clinical Cancer Research</i> , 2022, 28, 279-288.	3.2	10
2	Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. <i>Journal of Clinical Oncology</i> , 2022, 40, 1552-1561.	0.8	26
3	Phase II Study of Taselisib in <i>PIK3CA</i> -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. <i>JCO Precision Oncology</i> , 2022, 6, e2100424.	1.5	9
4	Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute. <i>Journal of Clinical Oncology</i> , 2022, 40, 1949-1957.	0.8	4
5	Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. <i>Npj Precision Oncology</i> , 2022, 6, 13.	2.3	18
6	Effect of Capivasertib in Patients With an <i>AKT1 E17K</i> -Mutated Tumor. <i>JAMA Oncology</i> , 2021, 7, 271.	3.4	49
7	Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i> -Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i> -Mutated Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2996-3004.	3.2	23
8	Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3834-3844.	3.2	36
9	Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas. <i>Cancer Research</i> , 2020, 80, 304-318.	0.4	71
10	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1021-1029.	3.0	138
11	Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). <i>Journal of Clinical Oncology</i> , 2020, 38, 3883-3894.	0.8	168
12	Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> <sup>V600E</sup> Mutations: Results of the NCI-MATCH Trial Subprotocol H. <i>Journal of Clinical Oncology</i> , 2020, 38, 3895-3904.	0.8	145
13	Phase 0 Radiopharmaceutical Agent Clinical Development. <i>Frontiers in Oncology</i> , 2020, 10, 1310.	1.3	8
14	Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. <i>Journal of Clinical Oncology</i> , 2020, 38, 2407-2417.	0.8	102
15	Evaluation of toxicities related to novel therapy in clinical trials for women with gynecologic cancer. <i>Cancer</i> , 2020, 126, 2139-2145.	2.0	2
16	Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). <i>Clinical Cancer Research</i> , 2020, 26, 1812-1819.	3.2	47
17	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2499-2511.	1.1	14
18	Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. <i>Annals of Oncology</i> , 2019, 30, 1821-1830.	0.6	99

#	ARTICLE	IF	CITATIONS
19	National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3259-3268.	0.8	19
20	Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 101-101.	0.8	29
21	Creating clinical trial designs that incorporate clinical outcome assessments. <i>Neuro-Oncology</i> , 2016, 18, ii21-ii25.	0.6	6
22	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 3227-3237.	3.2	85
23	Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv003-djv003.	3.0	52
24	Are We Ready for the 10% Solution?. <i>Oncologist</i> , 2014, 19, 439-440.	1.9	5
25	Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials. <i>Clinical Cancer Research</i> , 2014, 20, 4176-4185.	3.2	12
26	First-Line Therapy in Ovarian Cancer Trials. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 756-762.	1.2	82
27	Clinical Trials in Recurrent Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 771-775.	1.2	186
28	More Randomization in Phase II Trials: Necessary but not Sufficient. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1075-1077.	3.0	16
29	The statistics of phase 0 trials. <i>Statistics in Medicine</i> , 2010, 29, 1072-1076.	0.8	27
30	Reply to D.L. Raunig. <i>Journal of Clinical Oncology</i> , 2009, 27, e265-e265.	0.8	0
31	Early Average Change in Tumor Size in a Phase 2 Trial: Efficient Endpoint or False Promise?. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1422-1423.	3.0	12
32	CLINICAL TRIAL DESIGNS FOR CYTOSTATIC AGENTS AND AGENTS DIRECTED AT NOVEL MOLECULAR TARGETS. , 2006, , 365-378.		0
33	Phase II Multicenter Trial of Bevacizumab Plus Fluorouracil and Leucovorin in Patients With Advanced Refractory Colorectal Cancer: An NCI Treatment Referral Center Trial TRC-0301. <i>Journal of Clinical Oncology</i> , 2006, 24, 3354-3360.	0.8	178
34	Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. <i>British Journal of Cancer</i> , 2001, 84, 1424-1431.	2.9	723
35	THERAPEUTIC STUDIES. <i>Hematology/Oncology Clinics of North America</i> , 2000, 14, 849-876.	0.9	6
36	Secondary Leukemia or Myelodysplastic Syndrome After Treatment With Epipodophyllotoxins. <i>Journal of Clinical Oncology</i> , 1999, 17, 569-569.	0.8	282

#	ARTICLE	IF	CITATIONS
37	An Information-Intensive Approach to the Molecular Pharmacology of Cancer. <i>Science</i> , 1997, 275, 343-349.	6.0	1,127
38	Vaginal Clear Cell Adenocarcinoma in the United States. <i>Gynecologic Oncology</i> , 1996, 61, 113-115.	0.6	17
39	Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. <i>Cancer Research</i> , 1996, 56, 5211-6.	0.4	60
40	Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. <i>Annals of Thoracic Surgery</i> , 1995, 60, 615-623.	0.7	2,649
41	Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: Predicting biochemical mechanism of action. <i>Statistics in Medicine</i> , 1994, 13, 719-730.	0.8	40
42	A comparison of two phase I trial designs. <i>Statistics in Medicine</i> , 1994, 13, 1799-1806.	0.8	294
43	Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks. <i>Medical and Pediatric Oncology</i> , 1994, 23, 86-98.	1.0	166
44	Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's drug discovery program for cancer and AIDS. <i>Stem Cells</i> , 1994, 12, 13-22.	1.4	74
45	Malignant disease appearing late after operation for T1 N0 non-small-cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1993, 106, 1053-1058.	0.4	91
46	Pilot Study of Interleukin-2 and Lymphokine-Activated Killer Cells Combined With Immunomodulatory Doses of Chemotherapy and Sequenced With Interferon Alfa-2a in Patients With Metastatic Melanoma and Renal Cell Carcinoma. <i>Journal of the National Cancer Institute</i> , 1992, 84, 929-937.	3.0	34
47	Exploratory data analytic techniques to evaluate anticancer agents screened in a cell culture panel. <i>Journal of Biopharmaceutical Statistics</i> , 1992, 2, 31-48.	0.4	14
48	Neural computing in cancer drug development: predicting mechanism of action. <i>Science</i> , 1992, 258, 447-451.	6.0	302
49	Artists' offspring. <i>Nature</i> , 1992, 357, 106-106.	13.7	2
50	Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. <i>Cancer Research</i> , 1992, 52, 3029-34.	0.4	122
51	Patients with T1 N0 non-SCLC lung cancer. <i>Lung Cancer</i> , 1991, 7, 83.	0.9	33
52	MR imaging evaluation of endometrial carcinoma: results of an NCI cooperative study.. <i>Radiology</i> , 1991, 179, 829-832.	3.6	187
53	Comparison of In Vitro Anticancer-Drug-Screening Data Generated With a Tetrazolium Assay Versus a Protein Assay Against a Diverse Panel of Human Tumor Cell Lines. <i>Journal of the National Cancer Institute</i> , 1990, 82, 1113-1117.	3.0	868
54	Cancer recurrence after resection: T1 N0 non-small cell lung cancer. <i>Annals of Thoracic Surgery</i> , 1990, 49, 242-247.	0.7	229

#	ARTICLE	IF	CITATIONS
55	Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate. <i>Cancer Chemotherapy and Pharmacology</i> , 1988, 22, 147-52.	1.1	44
56	Combined modality treatment for resected advanced non-small cell lung cancer: local control and local recurrence. <i>International Journal of Radiation Oncology Biology Physics</i> , 1988, 15, 89-97.	0.4	41
57	Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies.. <i>Journal of Clinical Oncology</i> , 1984, 2, 1352-1358.	0.8	306
58	Monitoring rules for stopping accrual in comparative survival studies. <i>Contemporary Clinical Trials</i> , 1982, 3, 325-343.	2.0	15
59	Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. <i>Journal of Chronic Diseases</i> , 1981, 34, 469-479.	1.3	263